AzTrials
AzTrials

Atopic DermatitisTARGET-DERMNCT03661866

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

An observational study of Atopic Dermatitis and Alopecia Areata, run by Target PharmaSolutions, Inc. at 62 sites in 4 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. Read more about this study

Who is it for?
Any age
How many people
15,000 participants
Where
62 sitesin 4 countries
Study dates
21 Dec 2018to Dec 2050
How long will I take part?
50 Years
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Adults and children (all ages) with with Atopic Dermatitis or other IMISC been prescribed any dermatologic treatment.

Who may be able to join

  • 1. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment.
  • 2. Participant has plans for future visits at the site for continued management of IMISC.

Who cannot join

  • 1. Inability to provide written informed consent/assent.
  • 2. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).

Trial locations and contacts

62 sites in 4 countries.

62 sites in 4 countries

United States54 sites

  • Allergy Partners of Western North Carolina

    Asheville, North Carolina, 28801

  • Centurion Dermatology

    Brooklyn, New York, 11219

  • The University of Buffalo

    Buffalo, New York, 14203

  • UNC Dermatology

    Chapel Hill, North Carolina, 27516

  • The Medical University of South Carolina

    Charleston, South Carolina, 29425

  • Lurie Children's Hospital/Northwestern University

    Chicago, Illinois, 60611

  • Ohio State University

    Columbus, Ohio, 43215

  • Empire Dermatology

    East Syracuse, New York, 13057

  • Windsor Dermatology

    East Windsor, New Jersey, 08520

  • El Paso Dermatology Center

    El Paso, Texas, 79902

  • Forest Hills Dermatology Group

    Forest Hills, New York, 11375

  • Johnson Dermatology

    Fort Smith, Arkansas, 72916

  • First OC Dermatology

    Fountain Valley, California, 92708

  • Center for Dermatology Cosmetic and Laser Surgery

    Fremont, California, 94538

  • North Texas Center for Clinical Research

    Frisco, Texas, 75034

  • Feinstein Dermatology and Cosmetic Surgery

    Hollywood, Florida, 33021

  • Dawes Fretzin Dermatology/ Dawes Fretzin Clinical Research Group

    Indianapolis, Indiana, 46520

  • University of California

    Irvine, California, 92697

  • The University of Kansas Medical Center

    Kansas City, Kansas, 66160

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire, 03756

  • Asthma and Allergy Center

    Lewisville, Texas, 75067

  • South Lincoln Dermatology Clinic

    Lincoln, Nebraska, 68502

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, 72205

  • Arkansas Dermatology

    Little Rock, Arkansas, 72223

  • Family Allergy and Asthma Research Institute

    Louisville, Kentucky, 40215

  • North Sound Dermatology

    Mill Creek, Washington, 98012

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin, 53226

  • University of Minnesota

    Minneapolis, Minnesota, 55455

  • Carl Thornblade, MD, PLLC

    Missoula, Montana, 59808

  • Dermatology Center for Skin Health

    Morgantown, West Virginia, 26542

  • Allergy Associates of Utah

    Murray, Utah, 84107

  • University of Utah MidValley Dermatology

    Murray, Utah, 84107

  • Greenwich Village Dermatology

    New York, New York, 10012

  • Ichan School of Medicine

    New York, New York, 10029

  • Allergy, Asthma & Clinical Research Center

    Oklahoma City, Oklahoma, 73120

  • Advanced Dermatology of the Midlands

    Omaha, Nebraska, 68144

  • Allergy and Clinical Immunology

    Pittsburgh, Pennsylvania, 15241

  • Oregon Health and Science University

    Portland, Oregon, 97239

  • Integrated Dermatology of Massachusetts

    Quincy, Massachusetts, 02169

  • Virginia Commonwealth University

    Richmond, Virginia, 23219

  • Mayo Clinic

    Rochester, Minnesota, 55905

  • DermAssociates, LCC

    Rockville, Maryland, 20850

  • Advanced Allergy & Asthma, PLLC

    Rockville Centre, New York, 11570

  • University of California - San Diego/Rady Children's Hospital

    San Diego, California, 92123

  • Clear Dermatology & Aesthetics Center/Investigative MD

    Scottsdale, Arizona, 85255

  • Spokane Dermatology Clinic

    Spokane, Washington, 99202

  • Academic Alliance in Dermatology

    Tampa, Florida, 33614

  • Montefiore Medical Center

    The Bronx, New York, 10467

  • George Washington University

    Washington D.C., District of Columbia, 20037

  • Center for Clinical Studies

    Webster, Texas, 77598

  • Integrated Dermatology of West Palm Beach

    West Palm Beach, Florida, 33406

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina, 27157

  • University of Massachusetts Medical School

    Worcester, Massachusetts, 01605

  • Linda Susan Marcus

    Wyckoff, New Jersey, 07481

Other trials in United States

Canada4 sites

  • Innovaderm Research, Inc.

    Montreal, Quebec

  • Skin Centre for Dermatology

    Peterborough, Ontario

  • York Dermatology Clinic and Research Centre

    Richmond Hill, Ontario, L4B 1L1

  • Saskatoon Dermatology Centre

    Saskatoon, Saskatchewan

Other trials in Canada

Germany2 sites

  • Dr. Bernhard Korge

    Düren, North Rhine-Westphalia, 52349

  • UKSH- Institut für Entzündungsmedizin

    Lübeck, Schleswig-Holstein, 23538

Other trials in Germany

Spain2 sites

  • Hospital Clinic de Barcelona

    Barcelona

  • Hospital Universitario La Princesa

    Madrid

Other trials in Spain

About this study

Official title: A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions

TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Read the detailed description

TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

The duration of follow-up for participants enrolled in the EU is limited to 5-years. Those within in US and Canada may consent to indefinite follow-up.

Keywords
Atopic Dermatitis, IMISC, Registry, Observational, Immune-mediated Inflammatory Skin Conditions
Medical subject headings
Dermatitis, Atopic, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Urticaria

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Characterize IMISC Treatment Regimens in Clinical Practice

    Enable characterization of IMISC disease activity and comorbid medical conditions over time.

    Measured: 25 Years

  2. Evaluate Patient Outcomes in Clinical Practice

    Enable characterization of IMISC disease activity and comorbid medical conditions over time.

    Measured: 25 Years

  3. Evaluate Adverse Events of IMISC and treatment in Clinical Practice

    Enable characterization of IMISC disease activity and comorbid medical conditions over time.

    Measured: 25 Years

Secondary outcomes (3)

  1. Evaluate the relationship between IMISC and comorbid medical conditions

    Inform clinical practice by identifying the occurrence and impact of comorbid medical conditions on treatment regimens, utilize patient reported outcomes, and evaluate patient support programs.

    Measured: 25 Years

  2. Evaluate Patient Reported Outcome (PRO) measures

    Inform clinical practice by identifying the occurrence and impact of comorbid medical conditions on treatment regimens, utilize patient reported outcomes, and evaluate patient support programs.

    Measured: 25 Years

  3. Evaluate outcomes related to Patient Support Programs (PSPs)

    Inform clinical practice by identifying the occurrence and impact of comorbid medical conditions on treatment regimens, utilize patient reported outcomes, and evaluate patient support programs.

    Measured: 25 Years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Sep 2018
  2. Study start21 Dec 2018
  3. Primary completionDec 2050 (estimated)
  4. Study completionDec 2050 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
15,000 participants (estimated)
Target duration
50 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT03661866
Sponsor's protocol ID
TARGET-DERM
Acronym
TARGET-DERM
Status last verified
Mar 2026
First submitted
4 Sep 2018
Last updated
20 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Abuabara K, Silverberg JI, Simpson EL, Paller AS, Eichenfield LF, Bissonnette R, Krueger J, Harris JE, Dalfonso L, Watkins SE, Crawford JM, Thaci D, Guttman-Yassky E. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. BMJ Open. 2020 Nov 27;10(11):e039928. doi: 10.1136/bmjopen-2020-039928.

    PubMed 33247014

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in